Freedom of Information Request: 0893 2020/21

I’ve got a Freedom of Information query that I hope you’ll be able to help me with

Question 1

Within the last 2 years, has the institution accepted or is it currently accepting any of the following drugs free of charge or for a nominal charge (eg £1):

Rizankizumab (Skyrizi) – Yes

Guselkumab (Tremfya) – No

Brodalumab (Kyntheum) – Yes

Ixekizumab (Taltz) – No

Secukinumab (Cosentyx) – out come scheme as opposed to a FOC scheme

Tildrakizumab (Ilumetri) – No

Question 2

If yes to any of the above, are you able to say how long is the free of charge drug stock typically provided for each patient? For example, is it :

First dose

First month

First 3 months

Some other period?

• Rizankizumab (Skyrizi) – Until May 2020.
• Brodalumab (Kyntheum) – first 3 months

Question 3

If the Institution has not accepted manufacturer provision of free of charge drug stock, are you able to say what have been the reasons for this?

Generally, no interest from the clinical specialties.